Cigna Group Reports Officer and Director Changes

Ticker: CI · Form: 8-K · Filed: 2024-06-20T00:00:00.000Z

Sentiment: neutral

Topics: leadership-change, governance, officer-appointment, director-election

TL;DR

Cigna Group board and exec shake-up effective June 14th.

AI Summary

The Cigna Group filed an 8-K on June 20, 2024, reporting changes effective June 14, 2024. These changes include the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of the compensatory arrangements are not provided in this excerpt.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future company direction and performance.

Key Players & Entities

FAQ

What specific changes were made regarding directors and officers?

The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but does not specify the individuals involved or the exact nature of these changes in this excerpt.

Were there any changes to executive compensation arrangements?

Yes, the filing states that there were changes related to 'Compensatory Arrangements of Certain Officers'.

When were these reported changes effective?

The changes reported in the 8-K were effective as of June 14, 2024.

What is the filing date of this 8-K report?

This 8-K report was filed on June 20, 2024.

What is the principal executive office address for The Cigna Group?

The principal executive offices are located at 900 Cottage Grove Road, Bloomfield, Connecticut 06002.

From the Filing

0000950159-24-000218.txt : 20240620 0000950159-24-000218.hdr.sgml : 20240620 20240620161530 ACCESSION NUMBER: 0000950159-24-000218 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240614 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 241056409 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K The Cigna Group Form 8-K false 0001739940 0001739940 2024-06-14 2024-06-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K     CURRENT REPORT   Pursuant to Section 13 or 15(d) of the   Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) June 14, 2024   The Cigna Group   (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.)     900 Cottage Grove Road Bloomfield , Connecticut 06002   (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code:   ( 860 ) 226-6000   Not Applicable   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On June 14, 2024, The Cigna Group (the “Company” or “our”) appointed Jamie Kates as the Company’s Chief Accounting Officer, serving as the Company’s principal accounting officer, effective Ju

View on Read The Filing